CA3198938A1 - Treatment of kras mutant cancers - Google Patents

Treatment of kras mutant cancers

Info

Publication number
CA3198938A1
CA3198938A1 CA3198938A CA3198938A CA3198938A1 CA 3198938 A1 CA3198938 A1 CA 3198938A1 CA 3198938 A CA3198938 A CA 3198938A CA 3198938 A CA3198938 A CA 3198938A CA 3198938 A1 CA3198938 A1 CA 3198938A1
Authority
CA
Canada
Prior art keywords
treatment
kras mutant
mutant cancers
combination therapies
provides combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3198938A
Other languages
English (en)
French (fr)
Inventor
Sandra E. Wiley
Daniel P. Gold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lite Strategy Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3198938A1 publication Critical patent/CA3198938A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3198938A 2020-11-19 2021-11-19 Treatment of kras mutant cancers Pending CA3198938A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063115969P 2020-11-19 2020-11-19
US63/115,969 2020-11-19
US202163154652P 2021-02-26 2021-02-26
US63/154,652 2021-02-26
US202163158849P 2021-03-09 2021-03-09
US63/158,849 2021-03-09
US202163173361P 2021-04-10 2021-04-10
US63/173,361 2021-04-10
PCT/US2021/060151 WO2022109307A1 (en) 2020-11-19 2021-11-19 Treatment of kras mutant cancers

Publications (1)

Publication Number Publication Date
CA3198938A1 true CA3198938A1 (en) 2022-05-27

Family

ID=81709695

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3198938A Pending CA3198938A1 (en) 2020-11-19 2021-11-19 Treatment of kras mutant cancers

Country Status (9)

Country Link
US (1) US20240016781A1 (https=)
EP (1) EP4247806A4 (https=)
JP (1) JP2024500288A (https=)
KR (1) KR20230148144A (https=)
AU (1) AU2021381423A1 (https=)
CA (1) CA3198938A1 (https=)
IL (1) IL302925A (https=)
MX (1) MX2023005806A (https=)
WO (1) WO2022109307A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
EP4376839A4 (en) * 2021-07-26 2025-10-15 Vincerx Pharma Inc SELECTIVE CDK9 INHIBITOR FOR THE TREATMENT OF RAS MUTANT CANCER
CN119522225A (zh) 2022-09-29 2025-02-25 广州嘉越医药科技有限公司 大环衍生物及其应用
IL319991A (en) * 2022-10-03 2025-06-01 Prelude Therapeutics Inc Cancer treatment using combinations of SMARCA2 inhibitors and KRAS-targeted therapies
WO2024173833A1 (en) * 2023-02-16 2024-08-22 Mei Pharma, Inc. Combination of a cdk inhibitor and a flt3 inhibitor for the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563596B2 (en) * 2006-06-21 2013-10-22 Piramal Enterprises Limited Enantiomerically pure compounds for the treatment of proliferative disorders
CN104220066A (zh) * 2010-11-19 2014-12-17 皮拉马尔企业有限公司 紫杉醇和cdk抑制剂药物组合物
CN105530931B (zh) * 2013-07-12 2019-11-08 皮拉马尔企业有限公司 用于治疗黑素瘤的药物组合
RU2726367C2 (ru) * 2016-03-28 2020-07-13 Пресидж Байосайенсиз, Инк. Фармацевтические комбинации для лечения злокачественной опухоли
US20220175750A1 (en) * 2018-04-23 2022-06-09 The Regents Of The University Of California Sustained release formulation for local delivery of cdk9 inhibitors
WO2020046966A1 (en) * 2018-08-27 2020-03-05 Kura Oncology, Inc. Treatment of adenocarcinomas with mapk pathway inhibitors
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
AU2020271908B2 (en) * 2019-04-11 2025-12-04 Mei Pharma, Inc. Voruciclib poly morphs and methods of making and using thereof
CA3148504A1 (en) * 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
WO2022217133A1 (en) * 2021-04-10 2022-10-13 Mei Pharma, Inc. Voruciclib dosing regimens and methods of treatment including the same

Also Published As

Publication number Publication date
AU2021381423A1 (en) 2023-06-22
KR20230148144A (ko) 2023-10-24
WO2022109307A1 (en) 2022-05-27
US20240016781A1 (en) 2024-01-18
EP4247806A4 (en) 2024-11-13
IL302925A (en) 2023-07-01
JP2024500288A (ja) 2024-01-09
EP4247806A1 (en) 2023-09-27
AU2021381423A9 (en) 2024-02-08
MX2023005806A (es) 2023-07-31

Similar Documents

Publication Publication Date Title
CA3198938A1 (en) Treatment of kras mutant cancers
MX2025002170A (es) Inhibidores de kras g12c
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12021552482A1 (en) Compounds targeting prmt5
CR20220354A (es) Inhibidores de egfr
EP4356975A3 (en) Erbb/btk inhibitors
ZA202206923B (en) New methylquinazolinone derivatives
WO2021243280A3 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
AU2018271990A1 (en) Covalent inhibitors of KRAS
WO2016106331A8 (en) Mutant idh1 inhibitors useful for treating cancer
AU2002950217A0 (en) 8- Hydroxy Quinoline Derivatives
MX2023001071A (es) Tratamiento de la migraña.
WO2020033838A3 (en) Treatment of egfr-mutant cancer
PH12021552513A1 (en) Pyrrole compounds
MX2024003952A (es) Combinación que comprende atogepant para tratar la migraña.
MX2025001982A (es) Inhibidores de kif18a y usos de estos
TN2022000092A1 (en) Oral complement factor d inhibitors
MX2021007247A (es) Derivados de rapamicina.
PH12021552953A1 (en) Tricyclic compounds
PH12020551772A1 (en) Oxo-substituted compound
WO2018005444A3 (en) Methods for treating cancer
CR20230218A (es) Nuevos derivados de indazol acetileno
MX2021009717A (es) Sulfonamidas biciclicas.
WO2019195641A3 (en) 1,3,4-oxadiazoles as inhibitors of rho/mrtf/srf-mediated gene transcription and methods for use of the same
MX2025001671A (es) Combinaciones antineoplasicas que comprenden tratamiento dirigido

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241122

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251202